BioPharma Resources

Drug Trial Radar · NCT07403188

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

Jan 2041

Study completion Jan 2041

Sponsor

Lead sponsor
Kyverna TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Conditions

  • Refractory Lupus Nephritis
  • Myasthaenia Gravis
  • Stiff Person Syndrome
  • Rheumatoid Arthritis (RA)
  • Multiple Sclerosis
  • Dermatomyositis
  • Systemic Sclerosis (SSc)

Interventions

  • KYV-101Drug

    Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  2. Number of participants with new or recurrent malignancies as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  3. Number of participants with new or exacerbation of a pre-existing neurologic disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  4. Number of participants with new or exacerbation of a prior rheumatologic or other autoimmune disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  5. Number of participants with new hematologic disorders as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  6. Number of participants with new infections as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).Time frame: Up to 15 years from study entry
  7. Number of participants with positive Replication-Competent Lentivirus (RCL) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry
  8. Number of participants with positive Chimeric Antigen Receptor (CAR) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry
  9. Number of participants with positive Anti-Drug-Antibody (ADA) laboratory test results through Year 5 of long-term follow-up (LTFU).Time frame: Up to 5 years from study entry

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Colorado, Denver

    Denver, Colorado · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.